Lee Ainslie Curis Inc Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $0.99 $1,076 - $1,869	1,888 Added 0.03%	5,541,019 $4.6 Million
Q1 2023 May 15, 2023	SELL	$0.51 - $0.78 $8,398 - $12,844	-16,467 Reduced 0.3%	5,539,131 $3.32 Million
Q4 2022 Feb 14, 2023	SELL	$0.47 - $17.22 $1 Million - $36.8 Million	-2,137,424 Reduced 27.78%	5,555,598 $3.06 Million
Q1 2022 May 16, 2022	SELL	$2.31 - $5.13 $225,123 - $499,949	-97,456 Reduced 1.25%	7,693,022 $18.3 Million
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $947,801 - $1.72 Million	212,989 Added 2.81%	7,790,478 $37.1 Million
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $38.9 Million - $49.6 Million	5,607,753 Added 284.7%	7,577,489 $59.3 Million
Q2 2021 Aug 16, 2021	BUY	$7.45 - $16.27 $14.7 Million - $32 Million	1,969,736 New	1,969,736 $15.9 Million

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.